<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01160341</url>
  </required_header>
  <id_info>
    <org_study_id>GSM-072010</org_study_id>
    <nct_id>NCT01160341</nct_id>
  </id_info>
  <brief_title>Metabolic Syndrome Criteria and the Effect of Testosterone Treatment in Young Men With Hypogonadism</brief_title>
  <official_title>Phase 4 Study of About the Effect of Testosterone Treatment on the Components of Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gulhane School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gulhane School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to answer the following questions:

        1. Is hypogonadism a cause for the metabolic syndrome ?

        2. What is the effect of testosterone replacement on the metabolic parameters ?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a retrospective design, which is performed by investigating the registrations of
      patients with hypogonadotrophic hypogonadism between the years 2002-2009.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">312</enrollment>
  <condition>Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Testosteron, secondary hypogonadism</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosteron</intervention_name>
    <description>Testosteron 250mg injection per 3-4 weeks for 6 months</description>
    <arm_group_label>Testosteron, secondary hypogonadism</arm_group_label>
    <other_name>Sustanon 250mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men

          -  Congenital hypogonadism

          -  Treatment Naive

        Exclusion Criteria:

          -  Previous history of androgen replacement

          -  Hypertension

          -  Diabetes mellitus
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Gulhane School of Medicine</name>
      <address>
        <city>Ankara</city>
        <zip>06018</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006 Jul;60(7):762-9.</citation>
    <PMID>16846397</PMID>
  </reference>
  <reference>
    <citation>Araujo AB, O'Donnell AB, Brambilla DJ, Simpson WB, Longcope C, Matsumoto AM, McKinlay JB. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2004 Dec;89(12):5920-6.</citation>
    <PMID>15579737</PMID>
  </reference>
  <reference>
    <citation>Saad F, Gooren LJ, Haider A, Yassin A. A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. J Androl. 2008 Jan-Feb;29(1):102-5. Epub 2007 Oct 3.</citation>
    <PMID>17916569</PMID>
  </reference>
  <reference>
    <citation>Koesling D, Schultz G, BÃ¶hme E. Sequence homologies between guanylyl cyclases and structural analogies to other signal-transducing proteins. FEBS Lett. 1991 Mar 25;280(2):301-6. Review.</citation>
    <PMID>1672855</PMID>
  </reference>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2010</study_first_submitted>
  <study_first_submitted_qc>July 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2010</study_first_posted>
  <last_update_submitted>July 9, 2010</last_update_submitted>
  <last_update_submitted_qc>July 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Alper Sonmez</name_title>
    <organization>Gulhane School of Medicine Department of Endocrinology and Metabolism</organization>
  </responsible_party>
  <keyword>Metabolic syndrome</keyword>
  <keyword>Hypogonadism</keyword>
  <keyword>Testosterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

